Scientific Program
Wed
Thu
Fri
Sat
Wednesday, April 26, 2023
BREAST CANCER
| Welcome Adress of the Hosts and Greeting Words J.-U. Blohmer and J. Sehouli | |
LIVE SURGERY NSME, BCS, IOUS, SNB, Autologous and Allogenic Reconstructions, Lipofilling Moderation: F. Reyal, M. Karsten Surgeons: J.-U. Blohmer, O. Camara, J. Wagner, J. Kricheldorff, R. Reinemer, S. Paepke DURING LIVE SURGERY: The Most Challenging Case of the Year J. K. Wagner | |
| Lunch Break |
SYMPOSIUM (With kind support of AstraZeneca)
Paradigm Shift in Breast Cancer?
Chair: J.-U. Blohmer
| BRCAm Tumours – The Next Subtype? D. Speiser | |
| New Approaches in Metastatic Breast Cancer – HER2-Low and HR-Positive J. U. Blohmer | |
| Q & A |
PRESIDENTIAL LECTURES
Chairs: D. Speiser, F. Reyal
| New Strategies for Management of Patients with ER+/HER2-Breast Cancer and Progression on CDK 4/6 Inhibitors: From Targeted Therapies to ADC M. P. Goetz | |
| Do We Need More Technologies in Breast Surgery and Breast Reconstruction Like OPS, TAD, TAS, ICG-A, Synthetic Meshes, ADMs? J.-U. Blohmer |
STATE OF THE ART SESSION
Chairs: R. Leon Ferre, S. Kümmel
| Precision Surgery in Breast Cancer – Visualizing Breast Tumor Placement and Extent F. Reyal | |
| Hereditary Breast Cancer – Treatment of Early and Advanced Breast Cancer D. Speiser |
READY FOR PRIME TIME?
Chairs: V. Kiver, T. Haddad, D. Kaul
| Alarmbased PRO Monitoring – Ready for Clinical Implementation for All? M. Karsten | |
| Conventional Versus Hypofractionated Post-Mastectomy Proton Radiotherapy in HR-Deficient Tumors R. Mutter | |
| Coffee Break |
IMPORTANT AND ACTUAL QUESTIONS AND TOPICS
Chairs: M. P. Goetz, J.-U. Blohmer
| De-Escalation of Therapy in the Elderly Necessary and Possible? A. Lee | |
| Moving Clinical Trials to Home: Home-Based Care T. Haddad | |
| Patient-Derived Xenografts and/or Cancer Genom Sequence: Ready for Clinical Practice? V. Kiver | |
| What is Low-HER2 and Does it Matter in Clinical Decision? S. Kümmel | |
| New Strategies in the Neoadjuvant and Metastatic Setting for Triple-Negative Breast Cancer R. Leon Ferre | |
| New Models to Understand Unique Biology and Treatment Response in Invasive Lobular Carcinoma S. Oesterreich | |
| Development of a Breast Cancer Vaccine for Primary Prevention of Breast Cancer K. Knutson | |
| Discussion all speakers | |
| End of Program |
CMC Master Course
Parallel to main program (04:00 pm to 06:00 pm)
Surgical and Medical Management in Ovarian Cancer
J. Sehouli, S. Dowdy, C. Fotopoulou
Thursday, April 27, 2023
CERVICAL, ENDOMETRIAL CANCER, SARCOMA
LIVE SURGERY Sentinel Node, Radical Hysterectomy, Nerve-Sparing Techniques, ICG Techniques, Perioperative Management, Exenteration Moderation: A. Mariani, G. Glaser, A. Mustea, J. Sehouli (Plenary); R. Armbrust (Operating Room) Surgeons: M. Z. Muallem, V. Chiantera, G. Aletti, E. Delarue DURING LIVE SURGERY: The Most Challenging Case of the Year A. Kumar | |
| Lunch Break |
COLLOQUIUM (Funded by Eisai Europe Ltd.)
Priming and Practical Optimal Management Before, During and After Immunotherapy in Endometrial Cancer
| Distillation of current standard of care in immunotherapy N. Concin | |
| How to prepare patients before therapy? J. Sehouli | |
| How to monitor patients during therapy? B. Monk | |
| Long-term survivors in endometrial cancer – who they are R. Coleman | |
| Panel Discussion N. Concin, B. Monk, R. Coleman, J. Sehouli |
CERVICAL CANCER
Chairs: K. Pietzner, S. Dowdy, W. Lichtenegger
PRESIDENTIAL LECTURE | |
| How to Treat Best Advanced and Metastatic Cervical Cancer D. Cibula | |
OVERVIEW | |
| Best of Global Clinical Trials: Current and Planned Studies E. Roser | |
| CMC Exclusive! First Scientific Presentation: Charité Experience Regarding Alustents J. Neymeyer, R. Armbrust | |
PRO/CON DEBATE | |
| Open Versus Minimally Invasive Surgery in Cervical Cancer: Where are We Now After 5 Years of LACC? Open Surgery: C. Marth Minimally Invasive Surgery: G. Scambia Discussion: M. Z. Muallem, C. Marth, G. Scambia | |
| Coffee Break |
ENDOMETRIAL CANCER, SARCOMA
Chairs: A. Mariani, R. Chekerov, D. Lorusso
PRESIDENTIAL LECTURE | |
| New Standards in Advanced and Metastatic Endometrial Cancer M. R. Mirza | |
OVERVIEW | |
| Best of Global Clinical Trials: Current and Planned Studies T. Arndt | |
DEBATE | |
| Sentinel Node Biopsy Who Should Get It? N. Abu-Rustum Who Not? A. Mariani Discussion | |
HOTTEST TOPICS IN CLINICAL ROUTINE AND RESEARCH | |
| Newest Insights of Robotic Assisted Surgery in Endometrial Cancer M. Z. Muallem | |
| onsequence for Clinical Day and Science: Checkpoint Inhibitor after Checkpoint Inhibitor – Who Benefits, Who Not, How to Modify the Therapy? D. Lorusso | |
| Molecular Characterization in Endometrial Cancer: What are the Definitions, What are the Limitations? E. Taube | |
| What is the Best Therapy for Wild-Type and Mutant P53 Tumors? J. Sehouli | |
| Dostarlimab Plus Chemotherapy for the Treatment of Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): A Placebo (PBO)-Controlled Randomised Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) L. Hanker | |
| Discussion all speakers | |
| End of Program |
CMC Master Course
Parallel to main program (04:00 pm to 06:00 pm)
Surgical and Topographic Anatomy: Breast Cancer and Reconstructive Surgery
J.-U. Blohmer, O. Camara, S. Paepke, F. Reyal
Friday, April 28, 2023
OVARIAN CANCER
LIVE SURGERY | |
| Lunch Break |
SYMPOSIUM (With kind support of GlaxoSmithKline)
Rethinking Ovarian Cancer Treatment – From Ideas to Practice. Where are we Today? What are New Concepts for Tomorrow?
Chair: P. Harter
| Brief Introduction P. Harter | |
| Surgery – Challenging Optimal Timing P. Wimberger | |
| Chemotherapy – Challenging Historical Paradigms K. Pietzner | |
| Maintenance Therapy – Rethinking the Backbone J. Sehouli | |
| Summary P. Harter |
OVARIAN CANCER I
Chairs: C. Marth, A. Wahner-Hendrickson, M. R. Mirza
PRESIDENTIAL LECTURE | |
| How to Treat Best Advanced Ovarian Cancer? T. Herzog | |
OVERVIEW | |
| Best of Global Clinical Trials: Current and Planned Studies R. Armbrust | |
| CMC Exclusive! First Scientific Presentation: 20 Years Experience in Ovarian Cancer Surgery – Charité Berlin J. Sehouli | |
HOTTEST TOPICS IN CLINICAL ROUTINE AND RESEARCH | |
| What Can HRD Testing Really Predict, What Not? S. Weroha | |
| Real-World Evidence in Advanced Ovarian Cancer and its Clinical Implication J. Sehouli | |
| Current and Future Options for Patients with Relapsed Ovarian Cancer A. Wahner-Hendrickson | |
| Newest Insights of Immunotherapy in Gynecological Malignancies B. Monk | |
| Coffee Break |
OVARIAN CANCER II
Chairs: J. Sehouli, C. Fotopoulou, S. J. Weroha
LECTURES | |
| HIPEC, PIPAC and More – Where is their Real Place? P. Harter | |
| Surgical and Conservative Management of Bowel Obstruction in Ovarian Cancer C. Fotopoulou | |
| Secondary Malignancies: How to Prevent, How to Treat Best? L. Bullinger | |
| PARP After PARP Therapy: Who Can Really Benefit, Who Not? J. Ledermann | |
| Endometriosis-associated Ovarian Cancer and its Clinical Implications S. Mechsner | |
| Discussion all speakers | |
| End of Program |
CMC Master Course
Parallel to main program (05:30 pm to 07:30 pm)
Prerehabilitation, ERAS, Minimally Invasive Complication Management, Blood Management
S. Dowdy, A. Kumar, J. Sehouli, M. Lee, M. G. Inci-Turan,
F. Büttner
Saturday, April 29, 2023
GLOBAL HEALTH AND MOLECULAR DIAGNOSTICS AND PERSONALIZED THERAPIES IN ALL WOMEN’S CANCERS
INSIGHTS OF GLOBAL HEALTH PROGRAMS
Chairs: E. I. Braicu, G. Konecny
| 80 Minutes Around the World: Cervical Cancer Elimination Between Vision and Reality S. Nasser, M. Gültekin, A. Ulrich, A. Stepanyan | |
CMC AWARD LECTURE | |
| The Never-Ending HER2 Study D. Slamon | |
OVERVIEW | |
| Best of Clinical Trials in Rare Tumors J. Grabowski | |
| Coffee Break |
INSIGHTS OF CLINICAL DEBATES
Chairs: J. Sehouli, J.-U. Blohmer, A. Wahner-Hendrickson
| What is PARP Resistance and How to Overcome? E. I. Braicu | |
LECTURES | |
Antibody Drug Conjugate (ADC)
| |
| Evolution of Synchronous Bilateral Breast Cancers Provide Insights into Interactions Between Host, Tumor and Immunity F. Reyal | |
| Digital Patient T. Pross | |
Lunch Break POSTER SESSION (during lunch break) | |
SYMPOSIUM |
LECTURES
Chairs: J. Sehouli, J.-U. Blohmer, A. Wahner-Hendrickson
| Study Update GOG and ENGOT: Clinical Trial Landscape in GOG-ENGOT Collaboration R. Coleman | |
| Learning Lessons From Long-Term Survivors with Gynecological Cancer H. Woopen | |
| Molecular Tumor Conference E. I. Braicu |
CLOSING SESSION
| Presentation of the three Best Posters | |
| Closing Words and Farewell | |
| End of Program |
CMC Master Course
Parallel to main program (09:00 am to 11:00 am)
Urological Complication Management in Gynecological Oncology
J. Neymeyer, R. Chekerov
CMC Cadaver Course
Parallel to main program (08:00 am to 12:00 noon)
Gynecologic Oncology
M. Z. Muallem, A. Miranda, T. Jöns
CMC Cadaver Course
Parallel to main program (01:00 pm to 05:00 pm)
Breast Cancer
J.-U. Blohmer, O. Camara, T. Jöns
